Key Highlights

  • Shares fell 18.33% in pre-market trading to $23.80, down from a prior close of $29.14
  • Second quarter 2026 Revenue was $85.7 million, up 9% year over year, beating the $85.5 million estimate
  • Adjusted EPS of $0.34 beat the $0.14 estimate by 142.86%
  • Company cut full-year 2026 revenue guidance to a range of $360 million to $366 million from $360 million to $368 million
  • Adjusted EBITDA Margin expanded 180 basis points to 16.3%
  • Airway clearance inventory dynamics are expected to persist through the third quarter before normalizing in the fourth quarter
  • Market Capitalization stands at $657.29 million, with a 52-week range of $12.01 to $37.77

Shares Plunge Despite Beating Revenue and EPS Estimates

Tactile Systems Technology (NASDAQ:TCMD) shares were trading at $23.80 in pre-market activity on August 11, 2026, down 18.33% from the prior close of $29.14. The decline came despite the company beating both revenue and Earnings estimates for the second quarter of 2026, with revenue of $85.7 million topping the $85.5 million estimate and adjusted EPS of $0.34 beating the $0.14 estimate by a wide margin.

The scale of the stock's decline appears tied to the company's narrowed full-year 2026 revenue guidance, which now calls for $360 million to $366 million, the low end unchanged but the high end reduced from $368 million, falling short of the $364.8 million midpoint consensus. Investors also focused on a 7% sequential decline in Afflovest airway clearance revenue, which the company attributed to temporary inventory management dynamics among key durable medical equipment partners tied to the next-generation Afflovest launch.

What Tactile Systems Technology Does

Tactile Systems Technology, operating as Tactile Medical, is a Minneapolis, Minnesota-based medical technology company that designs, manufactures, and markets at-home medical devices for the treatment of underserved chronic conditions. Its core product portfolio includes the Flexitouch Plus and Entre pneumatic compression systems for managing lymphedema, chronic venous insufficiency, and venous leg ulcers, as well as the AffloVest, a portable high-frequency chest wall oscillation device for patients with retained pulmonary secretions from conditions like bronchiectasis and cystic fibrosis.

The company generates revenue primarily through direct sales and rentals of its devices, and related services, with a significant portion of revenue derived from Medicare and private insurance reimbursement for home-use therapy. Tactile Systems Technology employs over 1,000 people and trades on the Nasdaq Global Market, serving patients, clinicians, and durable medical equipment partners across the United States.

Segment Performance and Full-Year Guidance

Lymphedema revenue grew 12% year over year to $73.6 million, remaining the core growth driver for the business, while Afflovest airway clearance revenue declined 7% sequentially to $12.1 million due to temporary inventory management dynamics among key durable medical equipment partners tied to the next-generation Afflovest launch. Profitability improved meaningfully, with gross margin expanding 180 basis points to 76.3%, adjusted EBITDA rising 142% year over year to $11.4 million, and Net Income increasing 142% to $7.8 million, or $0.34 per diluted share, with cash balance standing at $69.9 million and no outstanding borrowings.

For the full year, the company updated total revenue guidance to $360 million to $366 million, representing growth of 9% to 11%, with lymphedema revenue growth now expected closer to 12% year over year due to inventory normalization, and adjusted EBITDA margin guidance maintained at 15% to 16%.

Strategic Initiatives and Airway Clearance Outlook

Strategic initiatives during the quarter included a distribution agreement with Aerobika Med for Myo sleeve targeting the ventilator-associated and deep vein thrombosis prophylaxis device markets, continued integration of the company's lymphatic diagnostic platform following FDA diagnostic aid clearance expected in 2027, and continued clinical evidence generation, including publication of a 236-patient head-and-neck lymphedema clinical trial supporting Flexitouch efficacy.

Management said airway clearance inventory dynamics are expected to persist through the third quarter before normalizing in the fourth quarter of 2026, as Medicare prior authorization requirements effective April 13 caused near-term order timing shifts in lymphedema but are expected to stabilize as adjudication processes mature.

Conclusion

Tactile Systems Technology's sharp pre-market decline despite beating both revenue and EPS estimates illustrates how narrowed forward guidance and softness in a specific product segment can outweigh an otherwise strong quarterly print in investor sentiment. With lymphedema revenue continuing to grow at a healthy double-digit pace and profitability metrics showing meaningful improvement, the company's core growth engine appears intact, but the market's reaction suggests investors want more clarity on when Afflovest airway clearance inventory dynamics will normalize before re-rating the stock higher.